Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery.

Area of Science:

• Biochemistry and Medicinal Chemistry
• Endocrinology and Metabolic Diseases

Background:

• Current antidiabetic treatments focus on weight reduction, with glucagon-like peptide-1 (GLP-1) receptor agonists like exendin-4 showing promise.
• Exendin-4, administered via subcutaneous injection, improves glycemic control and promotes weight loss but requires frequent dosing.

Purpose of the Study:

• To engineer exendin-4 for enhanced therapeutic efficacy, focusing on increased potency and serum half-life.
• To develop a novel peptide delivery system for improved patient compliance and therapeutic outcomes.

Main Methods:

• Peptide engineering strategy involving a serum protein binding motif and covalent side-chain stapling to enhance helicity, potency, and half-life.
• In vivo studies in rodents and guinea pigs to evaluate pharmacokinetic, pharmacodynamic, and metabolic effects of the engineered peptide (E6).
• Development and testing of a transdermal delivery system utilizing dissolvable microneedles for E6 administration.

Main Results:

• The engineered peptide E6 demonstrated significantly improved half-life and glucose tolerance in rodent models.
• Chronic E6 treatment in diet-induced obese mice led to decreased body weight, reduced fasting blood glucose, improved lipid metabolism, and ameliorated hepatic steatosis.
• Transdermal delivery of E6 via microneedles in guinea pigs resulted in sustained glucose tolerance improvement for 96 hours post-application.

Conclusions:

• Peptide engineering can enhance the therapeutic properties of GLP-1 receptor agonists, leading to improved metabolic control and reduced body weight.
• A transdermal microstructure-based delivery system offers a patient-friendly and effective alternative to injectable GLP-1 receptor agonists.
• This approach holds potential for the development of advanced peptide hormone therapies.